Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
Part of paid clinical trials in Mesa, Arizona.
- Sponsor
- Kyowa Kirin Co., Ltd.
- Study ID
- NCT06116890
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- KHK4951 — DRUGKHK4951 eye drop for 44 weeks until end of the trial
- Aflibercept Injection — DRUGIntravitreal injection (IVT) of aflibercept will be given as specified in the protocol
Study Details
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Key Dates
- Start date
- Jan 31, 2024
- Status verified
- Oct 2025
- Primary completion
- Aug 31, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 180 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm AKHK4951 High dose
- Experimental: Arm BKHK4951 Middle dose
- Experimental: Arm CKHK4951 Low dose
Primary Outcome Measure
Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline [ Time Frame: For 44 weeks until the end of the trial ]
Locations (38)
Find similar trials in Mesa, AZ
Related Studies
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDEnrolling By Invitation · AbbVie · Phoenix, Arizona
- A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular DegenerationPHASE3 · Not Yet Recruiting · Rophibio, Inc. · Phoenix, Arizona
- Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPHASE3 · Recruiting · 4D Molecular Therapeutics · Scottsdale, Arizona
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)PHASE3 · Recruiting · Adverum Biotechnologies, Inc. · Phoenix, Arizona